Index of reports
> Death (1301)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide death. The selected reports were submitted to the FDA during the sample period of about a year.
Reports 1 - 30 of 1301 Next >>
Possible Cyclophosphamide side effects in 57 year old female
Reported by a physician from Croatia (Local Name: Hrvatska) on 2012-08-27
Patient: 57 year old female
Reactions: Breast Cancer Metastatic, Paraneoplastic Dermatomyositis, Pulmonary Embolism
Adverse event resulted in: death
Drug(s) suspected as cause:
Capecitabine
Administration route: Oral
Indication: Breast Cancer
Cisplatin
Dosage: 6 cycles
Indication: Breast Cancer
Cyclophosphamide
Dosage: 6 cycles
Indication: Breast Cancer
Doxorubicin Hydrochloride
Dosage: 6 cycles
Indication: Breast Cancer
Gemcitabine Hydrochloride
Indication: Breast Cancer
Paclitaxel
Indication: Breast Cancer
Possible Cyclophosphamide side effects in 49 year old male
Reported by a physician from Norway on 2012-08-27
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: on day 8
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for standard cycles on day 1
Doxorubicin Hydrochloride
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Doxorubicin Hydrochloride
Dosage: on day 1,for standard cycles
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the standard cycles, day 1 to 3
Indication: Hodgkin's Disease
Prednisolone
Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: day 1 to 7
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: on day 8
Indication: Hodgkin's Disease
Possible Cyclophosphamide side effects in 49 year old male
Reported by a physician from Norway on 2012-08-27
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: 10000 iu, day 8 (2 escalated cycles)
Indication: Hodgkin's Disease
Bleomycin Sulfate
Dosage: 10000 iu, day 8 (4 standard cycles)
Cyclophosphamide
Dosage: 650 mg/m2, day 1 (4 standard cycles)
Cyclophosphamide
Dosage: 1250 mg/m2, day 1 (2 escalated cycles)
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2, day 1 (4 standard cycles)
Doxorubicin HCL
Dosage: 35 mg/m2, day 1 (2 escalated cycles)
Indication: Hodgkin's Disease
Etoposide
Dosage: 100 mg/m2, day 1-3 (4 standard cycles)
Etoposide
Dosage: 200 mg/m2, day 1-3 (2 escalated cycles)
Indication: Hodgkin's Disease
Prednisolone
Dosage: 40 mg/m2, day 1-14 (4 standard cycles)
Administration route: Oral
Prednisolone
Dosage: 40 mg/m2, day 1-14 (2 escalated cycles)
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 100 mg/m2, day 1-7 (2 escalated cycles)
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 100 mg/m2, day 1-7 (4 standard cycles)
Administration route: Oral
Vincristine
Dosage: 1.4 mg/m2, day 8 (2 escalated cycles)
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2, day 8 (4 standard cycles)
Possible Cyclophosphamide side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-24
Patient: male, weighing 103.1 kg (226.8 pounds)
Reactions: Plasmacytosis, Pneumonia, Mouth Haemorrhage, Pseudomonas Infection, Headache, Disease Progression, Death, Mucosal Inflammation, Pleural Effusion, Depressed Level of Consciousness, Abscess, Lethargy, RIB Fracture
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cisplatin
Indication: Multiple Myeloma
Cyclophosphamide
Indication: Multiple Myeloma
Dexamethasone
Indication: Multiple Myeloma
Doxorubicin Hydrochloride
Indication: Multiple Myeloma
Etoposide
Indication: Multiple Myeloma
Radiation Therapy NOS
Indication: Multiple Myeloma
Revlimid
Indication: Multiple Myeloma
Thalidomide
Indication: Multiple Myeloma
Velcade
Indication: Multiple Myeloma
Other drugs received by patient: Bendamustine Hydrochloride; Lenalidomide
Possible Cyclophosphamide side effects in 49 year old male
Reported by a physician from Norway on 2012-08-24
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: on day 8
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for standard cycles on day 1
Doxorubicin Hydrochloride
Dosage: on day 1,for standard cycles
Doxorubicin Hydrochloride
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the standard cycles, day 1 to 3
Indication: Hodgkin's Disease
Prednisolone
Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: day 1 to 7
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: on day 8
Indication: Hodgkin's Disease
Possible Cyclophosphamide side effects in female
Reported by a physician from Bulgaria on 2012-08-24
Patient: female, weighing 63.0 kg (138.6 pounds)
Reactions: Circulatory Collapse, Bone Marrow Failure
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1000 milligram
Indication: Multiple Myeloma
Start date: 2012-05-23
End date: 2012-05-25
Dexamethasone
Dosage: 40 milligram
Start date: 2012-06-02
End date: 2012-06-05
Dexamethasone
Dosage: 40 milligram
Indication: Multiple Myeloma
Start date: 2012-05-23
End date: 2012-05-26
Dexamethasone
Dosage: 20 milligram
Start date: 2012-05-16
End date: 2012-05-19
Doxorubicin Hydrochloride
Dosage: 80 milligram
Indication: Multiple Myeloma
Start date: 2012-05-26
End date: 2012-05-26
Revlimid
Dosage: 25 milligram
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-05-30
End date: 2012-06-07
Vincristine
Dosage: 2 milligram
Indication: Multiple Myeloma
Start date: 2012-05-26
End date: 2012-06-02
Other drugs received by patient: Milgamma; Dopamine HCL; Nexium; Atropine; Sodium Carbonate; Lyrica; Uromithexane; Electrolyte Infusions; Sodium Bicarbonate; Probitor; Tevagrastim
Possible Cyclophosphamide side effects in female
Reported by a physician from Thailand on 2012-08-24
Patient: female, weighing 57.4 kg (126.3 pounds)
Reactions: Neutropenia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Doxorubicin Hydrochloride
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Prednisone TAB
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-03-02
Other drugs received by patient: Dexamethasone; Acetaminophen; Ondansetron; Metformin HCL; Ondansetron; Ondansetron; Atenolol; Simvastatin; Benadryl
Possible Cyclophosphamide side effects in 52 year old female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-23
Patient: 52 year old female
Reactions: Neoplasm Malignant, Acute Myeloid Leukaemia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 6 courses at 500 mg/m2 (cumulative dose : 3000 mg/m2)
Indication: Breast Cancer
Start date: 1991-01-01
End date: 1991-01-01
Fluorouracil
Dosage: 6 courses at 500 mg/m2 m2 (cumulative dose : 3000 mg/m2)
Indication: Breast Cancer
Start date: 1991-01-01
End date: 1991-01-01
Novantrone
Dosage: 6 courses
Indication: Breast Cancer
Start date: 1991-01-01
End date: 1991-01-01
Possible Cyclophosphamide side effects in male
Reported by a physician from United States on 2012-08-23
Patient: male
Reactions: Death, Chalazion
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Multiple Myeloma
Dexamethasone
Indication: Multiple Myeloma
Lenalidomide
Indication: Multiple Myeloma
Velcade
Dosage: 2 mg, 1/week
Indication: Multiple Myeloma
Start date: 2009-08-13
End date: 2012-01-03
Other drugs received by patient: Bisphosphonates; Travoprost
Possible Cyclophosphamide side effects in 49 year old male
Reported by a physician from Norway on 2012-08-23
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Septic Shock, Lung Infiltration
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Baxter 15 000 IE Lyofilisat TIL Injeksjonsv?ske / Infusjonsv?s
Cyclophosphamide
Cyclophosphamide
Doxorubicin Hydrochloride
Doxorubicin Hydrochloride
Etoposide
Etoposide
Prednisolone
Administration route: Oral
Procarbazine Hydrochloride
Administration route: Oral
Vincristine
Possible Cyclophosphamide side effects in 51 year old male
Reported by a physician from Japan on 2012-08-22
Patient: 51 year old male, weighing 57.7 kg (126.9 pounds)
Reactions: Hypophosphataemia, Tumour Lysis Syndrome, Gastrointestinal Haemorrhage, Metabolic Acidosis, Hyperphosphataemia, Disseminated Intravascular Coagulation
Adverse event resulted in: death
Drug(s) suspected as cause:
Allopurinol
Dosage: 300 mg, unk
Allopurinol
Dosage: 200 mg, unk
Indication: Tumour Lysis Syndrome
Cyclophosphamide
Dosage: 1200 mg, unk
Indication: Lymphoma
Doxorubicin HCL
Dosage: 80 mg, unk
Indication: Lymphoma
Methylprednisolone
Dosage: 250 mg/day
Indication: Lymphoma
Methylprednisolone
Dosage: 60 mg/day
Sodium Bicarbonate
Indication: Metabolic Acidosis
Vincristine
Dosage: 2 mg, unk
Indication: Lymphoma
Possible Cyclophosphamide side effects in male
Reported by a physician from United States on 2012-08-22
Patient: male
Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Mantle Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Mantle Cell Lymphoma
Possible Cyclophosphamide side effects in male
Reported by a consumer/non-health professional from Germany on 2012-08-21
Patient: male, weighing 86.0 kg (189.2 pounds)
Reactions: Pneumonia, Pulmonary Embolism, Cytomegalovirus Infection, Pulmonary Infarction, Lymphoma, Staphylococcal Sepsis
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1500 mg, qd (day 1)
Indication: T-Cell Lymphoma
Start date: 2009-12-07
End date: 2010-01-11
Doxorubicin HCL
Dosage: 100 mg, qd (day 1)
Indication: T-Cell Lymphoma
Start date: 2009-12-07
End date: 2010-01-11
Filgrastim
Dosage: 48 unk, qd (day 1)
Indication: T-Cell Lymphoma
Start date: 2009-12-25
End date: 2010-01-15
Mabcampath
Dosage: 30 mg, day 4 and 5 of each cycle 1-3
Indication: T-Cell Lymphoma
Start date: 2009-12-10
End date: 2010-01-15
Prednisone
Dosage: 10 mg, qd (day 1-5)
Administration route: Oral
Indication: T-Cell Lymphoma
Start date: 2009-11-27
End date: 2010-01-10
Vincristine
Dosage: 1 mg, qd (day 1)
Indication: T-Cell Lymphoma
Start date: 2009-11-26
End date: 2010-01-11
Other drugs received by patient: Torsemide; Metoprolol Succinate; Heparin; Marcumar; Pantoprazole; Sulfamethoprim
Possible Cyclophosphamide side effects in 45 year old female
Reported by a physician from United States on 2012-08-21
Patient: 45 year old female
Reactions: Epstein-Barr Virus Infection, Splenic Infection Fungal, Mycosis Fungoides Refractory, Granuloma, Pneumonia Cytomegaloviral
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Campath
Dosage: unk
Indication: Mycosis Fungoides
Start date: 2006-06-01
Cisplatin
Dosage: unk
Indication: Mycosis Fungoides
Cyclophosphamide
Dosage: unk
Indication: Mycosis Fungoides
Start date: 2006-01-01
Daunorubicin HCL
Dosage: unk
Indication: Mycosis Fungoides
Start date: 2006-01-01
Dexamethasone
Dosage: unk
Indication: Mycosis Fungoides
Etoposide
Dosage: unk
Indication: Mycosis Fungoides
Fludara
Dosage: 2 cycles
Indication: Mycosis Fungoides
Ifosfamide
Dosage: unk
Indication: Mycosis Fungoides
Prednisone
Dosage: unk
Indication: Mycosis Fungoides
Start date: 2006-01-01
Vincristine
Dosage: unk
Indication: Mycosis Fungoides
Start date: 2006-01-01
Possible Cyclophosphamide side effects in 77 year old male
Reported by a health professional (non-physician/pharmacist) from China on 2012-08-21
Patient: 77 year old male
Reactions: Adverse Drug Reaction, Diffuse Large B-Cell Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Dexamethasone
Dosage: in cycle 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Methotrexate
Dosage: in cycle 1
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: on days 1 to 5
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Possible Cyclophosphamide side effects in male
Reported by a physician from United States on 2012-08-21
Patient: male, weighing 115.7 kg (254.5 pounds)
Reactions: Gastrointestinal Haemorrhage, Cholecystitis Acute, T-Cell Lymphoma, Disseminated Intravascular Coagulation, Pancytopenia, Atrial Fibrillation, Multi-Organ Failure, Sepsis, Acute Respiratory Distress Syndrome
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Adriamycin PFS
Indication: T-Cell Lymphoma
Start date: 2006-09-10
Cyclophosphamide
Indication: T-Cell Lymphoma
Start date: 2006-01-01
Prednisone TAB
Indication: T-Cell Lymphoma
Start date: 2006-01-01
Remicade
Dosage: 3 dose induction followed by maint. q 8 weeks, 300 mg on 29-jun-2006, total 27 infusions
Indication: Rheumatoid Arthritis
Start date: 2001-10-01
End date: 2006-06-29
Vincristine
Indication: T-Cell Lymphoma
Start date: 2006-09-10
Other drugs received by patient: Azulfadine; Lisinopril
Possible Cyclophosphamide side effects in
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-20
Patient:
Reactions: Death, Lymphoma, Diffuse Large B-Cell Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Prednisolone
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Cyclophosphamide side effects in 51 year old male
Reported by a physician from Japan on 2012-08-20
Patient: 51 year old male
Reactions: Hypophosphataemia, Metabolic Acidosis, Tumour Lysis Syndrome, Gastrointestinal Haemorrhage, Hyperphosphataemia, Disseminated Intravascular Coagulation
Adverse event resulted in: death
Drug(s) suspected as cause:
Allopurinol
Dosage: unk
Cyclophosphamide
Dosage: 1200 mg, unk
Indication: Lymphoma
Doxorubicin
Dosage: 80 mg, unk
Indication: Lymphoma
Methylprednisolone
Dosage: 60 mg/day
Methylprednisolone
Dosage: 250 mg/day
Indication: Lymphoma
Sodium Bicarbonate
Indication: Metabolic Acidosis
Vincristine
Dosage: 2 mg, unk
Indication: Lymphoma
Possible Cyclophosphamide side effects in female
Reported by a physician from Sweden on 2012-08-20
Patient: female
Reactions: Nausea, Progressive Multifocal Leukoencephalopathy, Hepatic Enzyme Increased
Adverse event resulted in: death
Drug(s) suspected as cause:
Azathioprine
Dosage: 150 mg/day
Administration route: Oral
Indication: Polymyositis
Cyclophosphamide
Dosage: 100 mg/day
Administration route: Oral
Indication: Polymyositis
Methotrexate
Dosage: 20 mg/week
Indication: Polymyositis
Methylprednisolone
Prednisone
Dosage: 10mg daily
Prednisone
Dosage: 17.5 mg/day
Administration route: Oral
Prednisone
Dosage: 60 mg/day
Prednisone
Dosage: 2.5 mg/day
Prednisone
Dosage: 40 mg/day
Indication: Polymyositis
Possible Cyclophosphamide side effects in female
Reported by a physician from Sweden on 2012-08-20
Patient: female
Reactions: Nausea, Progressive Multifocal Leukoencephalopathy, Hepatic Enzyme Increased
Adverse event resulted in: death
Drug(s) suspected as cause:
Azathioprine
Dosage: 150 mg/day
Administration route: Oral
Indication: Polymyositis
Cyclophosphamide
Dosage: 100 mg/day
Administration route: Oral
Indication: Polymyositis
Methotrexate
Dosage: 20 mg/week
Indication: Polymyositis
Methylprednisolone
Prednisone
Dosage: 40 mg/day
Indication: Polymyositis
Prednisone
Dosage: 10mg daily
Prednisone
Dosage: 17.5 mg/day
Administration route: Oral
Prednisone
Dosage: 60 mg/day
Prednisone
Dosage: 2.5 mg/day
Possible Cyclophosphamide side effects in
Reported by a physician from Germany on 2012-08-20
Patient:
Reactions: Infection
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: unk
Indication: Multiple Myeloma
Start date: 2012-03-26
End date: 2012-07-05
Dexamethasone
Dosage: unk
Indication: Multiple Myeloma
Start date: 2012-03-26
End date: 2012-07-05
Velcade
Dosage: unk
Indication: Multiple Myeloma
Start date: 2012-03-26
End date: 2012-07-05
Other drugs received by patient: Zometa; Amoxicillin
Possible Cyclophosphamide side effects in female
Reported by a physician from Sweden on 2012-08-20
Patient: female
Reactions: Nausea, Progressive Multifocal Leukoencephalopathy, Hepatic Enzyme Increased
Adverse event resulted in: death
Drug(s) suspected as cause:
Azathioprine
Dosage: 150 mg/day
Administration route: Oral
Indication: Polymyositis
Cyclophosphamide
Dosage: 100 mg/day
Administration route: Oral
Indication: Polymyositis
Methotrexate
Dosage: 20 mg/week
Indication: Polymyositis
Methylprednisolone
Prednisone
Dosage: 40 mg/day
Indication: Polymyositis
Prednisone
Dosage: 2.5 mg/day
Prednisone
Dosage: 10mg daily
Prednisone
Dosage: 60 mg/day
Prednisone
Dosage: 17.5 mg/day
Administration route: Oral
Possible Cyclophosphamide side effects in male
Reported by a physician from Japan on 2012-08-18
Patient: male
Reactions: Drug Eruption, Pneumonia, Oral Candidiasis, Oral Herpes, Decreased Appetite
Adverse event resulted in: death
Drug(s) suspected as cause:
Actonel
Administration route: Oral
Start date: 2009-05-26
End date: 2011-10-15
Aspirin
Administration route: Oral
Start date: 2006-12-22
End date: 2011-10-15
Cyclophosphamide
Administration route: Oral
Start date: 2009-05-25
End date: 2011-10-15
Cyclophosphamide
Administration route: Oral
Indication: Idiopathic Pulmonary Fibrosis
Start date: 2006-12-22
End date: 2007-03-19
Cyclophosphamide
Administration route: Oral
Start date: 2008-08-18
End date: 2009-05-24
Cyclophosphamide
Administration route: Oral
Start date: 2007-03-20
End date: 2008-08-17
Mucodyne
Administration route: Oral
Indication: Idiopathic Pulmonary Fibrosis
Start date: 2007-04-17
End date: 2011-10-15
Mucosolvan
Administration route: Oral
Indication: Idiopathic Pulmonary Fibrosis
Start date: 2007-10-23
End date: 2011-10-15
Pirfenidone
Dosage: 400 mg/am, 400 mg/pm, 600 mg night
Administration route: Oral
Start date: 2009-12-14
End date: 2010-07-07
Pirfenidone
Dosage: 600 mg/am, 600 mg/pm, 400 mg night
Administration route: Oral
Start date: 2010-07-07
End date: 2011-10-11
Pirfenidone
Dosage: 200 mg/am, 200 mg/pm, 400 mg night
Administration route: Oral
Start date: 2009-11-30
End date: 2009-12-14
Pirfenidone
Administration route: Oral
Indication: Idiopathic Pulmonary Fibrosis
Start date: 2009-11-16
End date: 2009-11-30
Povidone Iodine
Start date: 2009-05-27
End date: 2011-10-15
Prednisolone
Administration route: Oral
Indication: Idiopathic Pulmonary Fibrosis
Start date: 2006-12-22
End date: 2011-10-12
Prednisolone
Sulfamethoxazole and Trimethoprim
Administration route: Oral
Start date: 2007-03-21
End date: 2011-10-15
Zolpidem
Administration route: Oral
Start date: 2007-01-23
End date: 2011-10-15
Other drugs received by patient: Neoral; Flomox; Miconazole; Gentamicin Sulfate; Valtrex; Propeto; Neoral; Arasena-A; Olopatadine HCL; Hibidil; Myser
Possible Cyclophosphamide side effects in 37 year old male
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-17
Patient: 37 year old male
Reactions: Graft Versus Host Disease
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Thymoglobulin
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Other drugs received by patient: Methotrexate; Cyclosporine
Possible Cyclophosphamide side effects in 68 year old male
Reported by a health professional (non-physician/pharmacist) from Spain on 2012-08-17
Patient: 68 year old male
Reactions: Hepatitis B
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Splenic Marginal Zone Lymphoma
Doxorubicin Hydrochloride
Indication: Splenic Marginal Zone Lymphoma
Prednisone TAB
Indication: Immunosuppression
Rituxan
Indication: Splenic Marginal Zone Lymphoma
Vincristine
Indication: Splenic Marginal Zone Lymphoma
Possible Cyclophosphamide side effects in 1 year old female
Reported by a physician from Japan on 2012-08-17
Patient: 1 year old female
Reactions: Graft Versus Host Disease
Adverse event resulted in: death
Drug(s) suspected as cause:
Busulfan
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Cyclophosphamide
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Thymoglobulin
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Other drugs received by patient: Methotrexate; Cyclosporine
Possible Cyclophosphamide side effects in 4 year old male
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-17
Patient: 4 year old male
Reactions: Acute Graft Versus Host Disease
Adverse event resulted in: death
Drug(s) suspected as cause:
Busulfan
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Cyclophosphamide
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Thymoglobulin
Dosage: unk
Indication: Bone Marrow Conditioning Regimen
Other drugs received by patient: Methotrexate; Cyclosporine
Possible Cyclophosphamide side effects in male
Reported by a physician from Czech Republic on 2012-08-17
Patient: male, weighing 89.0 kg (195.8 pounds)
Reactions: Progressive Multifocal Leukoencephalopathy
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 500mg monthly
Indication: Chronic Lymphocytic Leukaemia
Start date: 2008-07-01
End date: 2008-11-20
Fludarabine Phosphate
Dosage: 50mg monthly
Indication: Chronic Lymphocytic Leukaemia
Start date: 2008-07-01
End date: 2008-11-20
Ofatumumab
Dosage: 1000mg monthly
Indication: Chronic Lymphocytic Leukaemia
Start date: 2008-06-30
End date: 2008-11-18
Possible Cyclophosphamide side effects in female
Reported by a physician from Netherlands on 2012-08-16
Patient: female, weighing 7.4 kg (16.3 pounds)
Reactions: Capillary Leak Syndrome, Hepatic Function Abnormal, Respiratory Failure, Disease Progression, Ascites
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Clofarabine
Dosage: 11 mg (40 mg/m2), qdx5
Indication: Acute Lymphocytic Leukaemia
Start date: 2010-07-23
End date: 2010-07-27
Cyclophosphamide
Dosage: 80 mg, qd
Indication: Acute Lymphocytic Leukaemia
Start date: 2010-07-23
End date: 2010-07-27
Cytarabine
Dosage: 15 mg, od
Indication: Acute Lymphocytic Leukaemia
Start date: 2010-07-28
End date: 2010-07-28
Cytarabine
Indication: Chemotherapy
Etoposide
Dosage: 28 mg, qd
Indication: Acute Lymphocytic Leukaemia
Start date: 2010-07-23
End date: 2010-07-27
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 6 mgr, od
Indication: Chemotherapy
Start date: 2010-07-28
End date: 2010-07-28
Prednisolone
Indication: Chemotherapy
Prednisolone
Dosage: 6 mgr, od
Indication: Acute Lymphocytic Leukaemia
Start date: 2010-07-28
End date: 2010-07-28
Other drugs received by patient: Itraconazole; Vancomycin; Dexamethasone; Filgrastim; Teicoplanin; Ciprofloxacin HCL; Ciprofloxacin HCL; Tramadol HCL; Vancomycin; Ceftazidime; Zofran; Vancomycin; Furosemide; Cotrim; Vancomycin; Vitamin K TAB; Cotrim; Itraconazole; Vancomycin; Vancomycin; Omeprazole; Acetaminophen; Ciprofloxacin; Furosemide; Ceftazidime; Furosemide; Omeprazole
Possible Cyclophosphamide side effects in
Reported by a individual with unspecified qualification from France on 2012-08-16
Patient:
Reactions: Zygomycosis
Adverse event resulted in: death
Drug(s) suspected as cause:
Alemtuzumab
Cyclophosphamide
Fludarabine Phosphate
Page 1 Next >>
|